Thomas J. Herzfeld Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-239	Closed	-$21K	–	269
2019 Q1	$21K	Sell	239 -12	-5%	-$1.11K	0.01%	206
2018 Q4	$21K	Buy	251 +46	+22%	+$4.38K	0.01%	208
2018 Q3	$20K	Sell	205 -111	-35%	-$11.1K	0.01%	197
2018 Q2	$30K	Hold	316	–	–	0.01%	199
2018 Q1	$26K	Buy	316 +105	+50%	+$9.01K	0.01%	219
2017 Q4	$19K	Sell	211 -189	-47%	-$16.4K	0.01%	234
2017 Q3	$37K	Hold	400	–	–	0.02%	201
2017 Q2	$36K	Hold	400	–	–	0.02%	197
2017 Q1	$35K	Hold	400	–	–	0.02%	230
2016 Q4	$33K	Hold	400	–	–	0.02%	234
2016 Q3	$37K	Hold	400	–	–	0.02%	200
2016 Q2	$31K	Hold	400	–	–	0.02%	243
2016 Q1	$33K	Hold	400	–	–	0.02%	253
2015 Q4	$42K	Hold	400	–	–	0.02%	210
2015 Q3	$42K	Buy	+400	New	+$53.4K	0.02%	199

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Thomas J. Herzfeld Advisors's BMRN Position: Q2 2019 in Review

Thomas J. Herzfeld Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 239 shares — an estimated $21K sold.

Thomas J. Herzfeld Advisors first reported a position in BMRN in Q3 2015 and held it in 15 quarters. The position peaked at $42K in Q4 2015. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Thomas J. Herzfeld Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 239 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $21K.
Thomas J. Herzfeld Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 15 quarters.
Thomas J. Herzfeld Advisors's BioMarin Pharmaceuticals position peaked at $42K in Q4 2015.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.